Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder

International Clinical Psychopharmacology

Volumn 24, Issue 6, 2009, Pages 306-311

  Dougherty, Darin D ^a   Jameson, Mariko ^a   Deckersbach, Thilo ^a   Loh, Rebecca ^b   Thompson Hollands, Johanna ^a   Jenike, Michael ^a   Keuthen, Nancy J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Compulsions; Escitalopram; Obsessions; Obsessive compulsive disorder; Selective serotonin reuptake inhibitors

Indexed keywords

ESCITALOPRAM; CITALOPRAM;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; INSOMNIA; MALE; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; XEROSTOMIA; ADOLESCENT; HOSPITALIZATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE;

ADOLESCENT; ADULT; CITALOPRAM; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 73949152555     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32833119d8     Document Type: Article

References (17)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders DSM-IV-TR Fourth Edition (Text Revision).
2. Bareggi SR, Bianchi L, Cavallaro R, Gervasoni M, Siliprand F, Bellodi L (2004). Citalopram concentrations and response in obsessive-compulsive disorder. CNS Drugs 18:329-335. (Pubitemid 38526715)
3. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
4. Beck AT, Epstein N, Brown G, Steer RA (1988). An inventory for measuring clinical anxiety: the Beck Anxiety Inventory. J Consult Clin Psychol 56:893-897. (Pubitemid 19008360)
5. Endicott J, Nee I, Harrison W, Blumenthal R (1993). Quality of Life, Enjoyment, and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321-326. (Pubitemid 23311543)
6. Fineberg NA, Gale TM (2005). Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8:107-129.
7. Fineberg NA, Tonnoir B, Lemming O, Stein DJ (2007). Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17:430-439. (Pubitemid 46497661)
8. First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured Clinical Interview for the DSM-IV Axis I disorders-Patient Edition (SCID-I/P, version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute.
9. Galvao-de Almeida A, Quarantini LC, Gois CR, Santos-Jesus R, Miranda-Scippa AM, de Oliveira IR, et al. (2007). Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. CWS Spectr 12:519-524.
10. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischman RL, Hill CL, et al. (1989a). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011. (Pubitemid 19278229)
11. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. (1989b). The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46:1011-1016.
12. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. US Dept of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; pp. 218-222.
13. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatr 23:56-62.
14. Karno M, Golding JM, Sorenson SB, Burnam MA (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45:1094-1099. (Pubitemid 19005463)
15. Montgomery SA, Kasper S, Stein DJ, BangHedegaard K, Lemming OM (2001). Citalopram 20, 40 and 60 mg are all effective and well tolerated compared with placebo in obsessive compulsive disorder. Int Clin Psychopharmacol 16:75-86. (Pubitemid 32171832)
16. Stein DJ, Andersen EW, Tonnoir B, Fineberg N (2007). Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 23:701-711. (Pubitemid 46631473)
17. Stewart SE, Dougherty DD, Wilhelm S, Keuthen NJ, Jenike MA (2007). OCD and OCD-related disorders. In: Stern TA, Rosenbaum JF, Fava M, Biederman J, Rauch S, editor. Massachusetts general hospital comprehensive clinical psychiatry. 1 ed. Boston: Mosby; pp. 447-464.